Although the physiological evidence suggests an inverse relationship between GLP-1 agonism and sexual desire, we posit that this relationship is difficult to observe in clinical practice, particularly due to the competing factors influencing sexual desire in patients undergoing obesity treatment through the use of GLP-1 agonists. The gene discussed is GCG; the disease is obesity disorder.